Methods and compositions for treating for the synergistic treatment of fungal associated disorders are discussed.
|
10. A pharmaceutical composition comprising an effective amount of a substituted tetracycline compound and an effective amount of an antifungal agent, and a pharmaceutically acceptable carrier, wherein the substituted tetracycline compound is selected from the group consisting of:
##STR00638##
##STR00639##
##STR00640##
##STR00641##
and pharmaceutically acceptable salts and enantiomers thereof;
further wherein said antifungal agent is selected from the group consisting of: fluconazole, itraconazole, ketoconazole, miconazole, clotrimazole, voriconazole, posaconazole, ravuconazole, natamycin, lucensomycin, nystatin, amphotericin B and caspofungin acetate; and
further wherein said pharmaceutical composition is effective against one or more fungi selected from the group consisting of: Aspergillus flavus, Aspergillus fumigatus, Aspergillus terreus, Candida albicans, Candida glabrata, Candida guilliermondii, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans, Issatchenkia orientalis, and Saccharomyces cerevisiae.
1. A pharmaceutical composition comprising an effective amount of a substituted tetracycline compound and an effective amount of an antifungal agent, and a pharmaceutically acceptable carrier, wherein the substituted tetracycline compound is of formula (I):
##STR00612##
wherein
X is CR6′R6;
R2 and R2′ are each hydrogen;
R4′ and R4″ are each alkyl;
R4 is NR4′R4″;
R3, R10, R11 and R12 are each hydrogen;
R5 is hydroxyl or hydrogen;
R6 and R6′ are each independently hydrogen or alkyl;
R7 is unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted aryl, alkoxy, unsubstituted or substituted alkylcarbonyl, or —(CH2)0-3NR7cC(═W′)WR7a;
R9 is hydrogen;
W is CR7dR7e, S, NR7b or O;
W′ is O, NR7e or S;
R7a, R7b, R7c, R7d and R7e are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic or heteroaromatic;
R8 is hydrogen;
further wherein said antifungal agent is selected from the group consisting of: fluconazole, itraconazole, ketoconazole, miconazole, clotrimazole, voriconazole, posaconazole, ravuconazole, natamycin, lucensomycin, nystatin, amphotericin B and caspofungin acetate, and
further wherein said pharmaceutical composition is effective against one or more fungi selected from the group consisting of: Aspergillus flavus, Aspergillus fumigatus, Aspergillus terreus, Candida albicans, Candida glabrata, Candida guilliermondii, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans, Issatchenkia orientalis, and Saccharomyces cerevisiae.
6. A pharmaceutical composition comprising an effective amount of a substituted tetracycline compound and an effective amount of an antifungal agent, and a pharmaceutically acceptable carrier, wherein the substituted tetracycline compound is of formula (I):
##STR00637##
wherein
X is CR6′R6;
R2 and R2′ are each hydrogen;
R4′ and R4″ are each alkyl;
R4 is NR4′R4″;
R3, R10, R11 and R12 are each hydrogen;
R5 is hydroxyl or hydrogen;
R6 and R6′ are each independently hydrogen or alkyl;
R7 is halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted aryl, alkoxy, unsubstituted or substituted alkylcarbonyl, or —(CH2)0-3NR7cC(═W′)WR7a;
R9 is halogen, nitro, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted aryl, alkoxy, unsubstituted or substituted alkylcarbonyl, or —(CH2)0-3NR9cC(═Z′)ZR9a;
Z is CR9dR9e, S, NR9b or O;
Z′ is O, S, or NR9e;
W is CR7dR7e, S, NR7b or O;
W′ is O, NR7e or S;
R7a, R7b, R7c, R7d, R7e, R9a, R9b, R9c, R9d and R9e are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic or heteroaromatic;
R8 is hydrogen;
further wherein said antifungal agent is selected from the group consisting of: fluconazole, itraconazole, ketoconazole, miconazole, clotrimazole, voriconazole, posaconazole, ravuconazole, natamycin, lucensomycin, nystatin, amphotericin B and caspofungin acetate, and
further wherein said pharmaceutical composition is effective against one or more fungi selected from the group consisting of: Aspergillus flavus, Aspergillus fumigatus, Aspergillus terreus, Candida albicans, Candida glabrata, Candida guilliermondii, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans, Issatchenkia orientalis, and Saccharomyces cerevisiae.
2. The pharmaceutical composition of
3. The pharmaceutical composition of
4. The pharmaceutical composition of
5. The pharmaceutical composition of
##STR00613##
##STR00614##
##STR00615##
##STR00616##
##STR00617##
##STR00618##
##STR00619##
##STR00620##
##STR00621##
##STR00622##
##STR00623##
##STR00624##
##STR00625##
##STR00626##
##STR00627##
##STR00628##
##STR00629##
##STR00630##
##STR00631##
##STR00632##
##STR00633##
##STR00634##
##STR00635##
##STR00636##
pharmaceutically acceptable salts and enantiomers thereof.
7. The pharmaceutical composition of
8. The pharmaceutical composition of
9. The pharmaceutical composition of
11. The pharmaceutical composition of
12. The pharmaceutical composition of
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a continuation of application Ser. No. 10/097,634, filed Mar. 14, 2002, now U.S. Pat. No. 7,045,507 which claims the benefit of U.S. Provisional Application No. 60/275,899, filed Mar. 14, 2001. The entire contents of these applications are hereby incorporated by reference in their entirety.
For many years, the development of effective therapeutic agents for fungal diseases (mycoses) has lacked the attention devoted to drugs effective against threatening, and provide little medical impetus to pharmaceutical companies to develop novel treatments. This scenario is changing, however, and while death from fungal disease is not new, the incidence of systemic fungal infections that cause these fatalities is increasing. Ironically, advances in modern medical techniques in other fields (immunosuppressive and/or cytotoxic therapy) and the advent of disease such as Acquired Immuno Deficiency Syndrome (AIDS) are major contributing causes to the increased number of serious fungal infections.
Fungal disorders can, thus, be divided into the life-threatening systemic infections, such as histoplasmosis, systemic candidiasis, aspergillosis, blastomycosis, coccidioidomycosis, paracoccidioidomycosis, and cryptococcosis, and the more common superficial ones, such as dermatophyte (ringworm) infections, for example, tinea pedis (athlete's foot) and tinea cruris (jock itch), candidiasis, and actinomycosis. The life-threatening fungal infections are a growing problem not only for immunosuppressed or immunocompromised individuals as noted above but individuals with other viral infections, such as cytomegalovirus (CMV), and influenza, for cancer patients receiving chemotherapy or radiotherapy, for transplant patients receiving antirejection agents, and for patients that have received toxic chemicals, metals and radiation exposure.
Mycoses are often caused by fungi which are opportunists, rather than pathogens. Candidiasis, aspergillosis, phycomycosis, nocardiosis, and cryptococcosis are typically opportunistic fungal infections. For example, Candida albicans, is normally found in the alimentary tract as a commensal, yet it is a major cause of systemic fungal infections in immunocomprised patients and topical infections in healthy individuals.
Most drugs currently available for the treatment of mycoses have limited efficacy or are poorly tolerated. A persistent and vexatious problem with antifungal agents, other infective organisms. The most common mycotic infections are superficial in nature, are not life largely unattended by the prior art, is the lack of an agent that is easy and economical to synthesize, and possesses high activity and broad spectrum activity against organisms, low toxicity and limited adverse effects.
Moreover, many known agents merely have fungistatic properties, rather than fungicidal properties. Fungistatic activity is the ability to prevent growth of fungi, while fungicidal (fungitoxic) activity is the ability to kill the fungi. Many agents used in the treatment of superficial mycoses are virtually devoid of either fungistatic or fungicidal actions in the concentrations used, and their beneficial effects probably depend upon factors not related to any direct effect on fungi.
Despite a plethora of agents which have or are alleged to have antifungal properties, most are simply fungistatic and not fungitoxic. For those that are fungicidal, for example, amphotericin B, there are severe adverse side effects which limit their use and their chemical properties, e.g., solubility, limit drug delivery method.
The invention pertains, at least in part, to methods for increasing the antifungal activity of an antifungal agent. The method includes administering the antifungal agent with an effective amount of a substituted tetracycline compound, such that the antifungal activity of the antifungal agent is increased. Examples of antifungal agents include polyenes such as amphotericin B. Examples of substituted tetracycline compounds include compounds of formula I:
##STR00001##
In an embodiment, the invention includes methods for treating fungal associated disorders in subjects. The methods include administering to a subject an effective amount of a substituted tetracycline compound in combination with an antifungal agent such that the subject is treated for the fungal associated disorder.
The invention also pertains, at least in part, to methods for treating fungal associated disorders in mammals. The method includes administering to the mammal a synergistically effective amount of a substituted tetracycline compound in combination with an effective amount of amphotericin B, such that the mammal is treated for the fungal associated disorder.
In another embodiment, the invention pertains to a pharmaceutical composition which contains a synergistically effective amount of a substituted tetracycline compound, an effective amount of an antifungal agent, and, optionally, a pharmaceutically acceptable carrier.
The invention also pertains, at least in part, to a method for killing fungus. The method includes contacting the fungus with a synergistically effective amount of a substituted tetracycline compound and a effective amount of an antifungal agent.
Although opportunistic systemic fungal infections have a high morbidity and mortality and their incidence is increasing, the art has yet to provide a safe, effective water soluble, simple-to-synthesize, fungitoxic agent with a broad antifungal spectrum of activity coupled with limited adverse effects and low toxicity.
The invention pertains, at least in part, to methods for increasing the antifungal activity of an antifungal agent, by administering an antifungal agent in combination with an effective amount of a substituted tetracycline compound. Previously, unsubstituted minocycline and doxycycline have been shown to possess limited antifungal activity both alone and in synergy with amphotericin B (Antimicrob. Agents Chemother. (1984), 26 (6) 837-40; Pathol. Biol. (1975) 23(9):725-8). However, both unsubstituted minocycline and doxycycline are limited by both low synergistic activity as well as high levels of cytotoxicity.
The terms “fungus” or “fungi” include a variety of nucleated, sporebearing organisms which are devoid of chlorophyll. Examples include yeasts, mildews, molds, rusts, and mushrooms. Examples of fungi include, but are not limited to Aspergillus fumigatus, Aspergillus flavus, Aspergillus nidulans, Candida albicans, Candida glabrata, Candida guilliermondii, Candida krusei, Candida lusitaniae, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans, Issatchenkia orientalis, Coccidioides, Paracoccidioides, Histoplasma, Blastomyces, and Neurospora crassa. In one embodiment, the fungi of the invention includes fungi of the genus Candida (e.g., C. tropicalis, C. parapsilosis, C. lusitaniae, C. krusei, C. guilliermondii, C. glabrata, C. dubliniensis, and C. albicans).
The term “antifungal agent” includes agents which are known in the art to have fungistatic or fungicidal activity, which can be synergistically increased using the compounds of the invention. Examples of antifungal agents include but are not limited to, azoles (e.g., Fluconazole®, Itraconazole®, Ketoconazole®, Miconazole®, Clortrimazole®, Voriconazole ®, Posaconazole®, Rovuconazole®, etc.), polyenes (e.g., natamycin, lucensomycin, nystatin, amphotericin B, etc.), echinocandins (e.g., Cancidas®), pradimicins (e.g., beanomicins, nikkomycins, sordarins, allylamines, etc.) and derivatives and analogs thereof.
The term “antifungal activity” includes inhibiting the growth of a fungus (e.g., fungistatic activity), killing at least a portion of the fungus (e.g., fungicidal activity), limiting the ability of the fungus to reproduce, etc.
The term “inhibiting the growth of a fungus” includes both fungistatic and fungicidal activity. Fungistatic activity includes any decrease in the rate of growth of a fungal colony. Fungistatic activity may be manifested by a fungus maintaining its present size or failing to colonize the surrounding areas. Fungistatic activity may be a result of inhibition of the fungal reproductive processes. Fungicidal activity generally includes, for example, irraditication of a fungus or fungal colony, killing a fungus or fungal colony or, in one embodiment, a decrease in the mass or size of a fungus or fungal colony.
In one embodiment, the antifungal activity of the antifungal agent is increased when administered in combination with a substituted tetracycline compound of the invention, thereby reducing the effective amount of the antifungal agent required as compared to the amount required when the antifungal agent is administered alone. In one embodiment, the coadministration of a substituted tetracycline compound of the invention reduces the effective amount of the antifungal agent by 1 fold, 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, or 10 fold, as compared to the effective amount of the antifungal agent alone, e.g., without the aid of a substituted tetracycline compound or another synergistic agent. Advantageously, the substituted tetracycline compound has low cell toxicity and may exhibit low (or, in some embodiments, no) antibacterial activity, e.g., as measured in Example 4. Substituted tetracycline compounds with low antibacterial activity may be compounds with MIC of 4 μm or greater. In certain embodiments, the substituted tetracycline compounds of the invention may have anti-inflammatory activity, e.g., as measured by art recognized assays. The cell toxicity of particular substituted tetracycline compounds, antifungal agents, and combinations thereof can be measured using the assay given in Example 3.
The language “effective amount” of the antifungal agent is the amount necessary or sufficient to inhibit the growth of fungus, or in certain instances, to kill the fungus. In an embodiment, the effective amount of the antifungal agent is reduced when administered in combination with a substituted tetracycline compound of the invention.
The term “tetracycline compounds” includes tetracycline family members such as methacycline, sancycline, apicycline, clomocycline, guamecycline, meglucycline, mepylcycline, penimepicycline, pipacycline, etamocycline, penimocycline, etc. as well as other tetracycline compounds having the characteristic naphthacene A-B-C-D ring structure. Additional tetracycline compounds can be found, for example, in U.S. patent application Ser. No. 09/234,847, and U.S. Pat. Nos. 5,834,450; 5,532,227; 5,789,395; 5,639,742 and German patents DE 28 14 974 and DE 28 20 983. The entire contents of the aforementioned applications and patents are hereby expressly incorporated herein by reference.
Recent research efforts have focused on developing new tetracycline compositions effective under varying therapeutic conditions and routes of administration; and for developing new tetracycline analogues which might prove to be equal or more effective as antibiotics than the originally introduced tetracycline families (See, U.S. Pat. Nos. 3,957,980; 3,674,859; 2,980,584; 2,990,331; 3,062,717; 3,557,280; 4,018,889; 4,024,272; 4,126,680; 3,454,697; and 3,165,531).
The term “substituted tetracycline compounds” includes tetracycline compounds which have at least one substitution, e.g., at the 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11a, 12, 12a, or, for methacycline, the 13 position, which allows the compound to perform its intended function, e.g., synergistically inhibit the growth of fungus. In an embodiment, the term “substituted tetracycline compounds” does not include unsubstituted tetracycline, minocycline, or doxycycline. In an embodiment, the substituted tetracycline compounds of the invention reduce the MIC of amphotericin B to a larger extent than unsubstituted doxycycline, tetracycline, or minocycline. The term “substituted tetracycline compound” includes, for example, substituted sancycline compounds, substituted minocycline compounds and substituted doxycycline compounds. In one embodiment, the FIC of a substituted tetracycline compound of the invention is 0.125 or less, 0.09 or less, 0.08 or less, 0.07 or less, 0.063 or less, etc. Values and ranges included and/or intermediate within the ranges set forth herein are also intended to be within the scope of the present invention.
Substituted tetracycline compounds used in the methods and compositions of the invention include compounds of Formula I:
##STR00002##
In an embodiment, the substituted tetracycline compounds used in the methods and compositions of the invention are substituted sancycline compounds, e.g., with substitution at the, for example, 2, 5, 6, 7, 8, 9, 10, 11, 11a, 12 12a position and/or, in the case of minocycline, 13. In substituted sancycline compounds of the invention, R2′, R3, R10, R11, and R12 are each hydrogen or a prodrug moiety; R4′ and R4″ are each alkyl (e.g., lower alkyl, e.g., methyl); X is CR6R6′; and R2, R5, R6, R6′, and R8 are each, generally, hydrogen. In other embodiments, In an embodiment, the substituted tetracycline compound is a substituted tetracycline (e.g., generally, wherein R4 is NR4′R4″, R4′ and R4″ are methyl, R5 is hydrogen and X is CR6R6′, wherein R6 is methyl and R6′ is hydroxy); substituted doxycycline (e.g., wherein R4 is NR4′R4″, R4′ and R4″ are methyl, R5 is hydroxyl and X is CR6R6′, wherein R6 is methyl and R6′ is hydrogen); substituted minocycline (e.g., wherein R4 is NR4′R4″ R4′ and R4″ are methyl; R5 is hydrogen and X is CR6R6 wherein R6 and R6′ are hydrogen atoms and R7 is dimethylamino) or substituted sancycline (wherein R4 is NR4′R4″, R4′ and R4″ are methyl; R5 is hydrogen and X is CR6R6′ wherein R6 and R6′ are hydrogen atoms).
In one embodiment, R5 is substituted, e.g., not hydrogen or hydroxy. In a further embodiment R5 is an ester (alkcarbonyloxy). In an embodiment, R5 is an alkyl ester. Examples of R5 include alkyl esters such as C1-C12 alkyl, alkenyl, alkynyl, or aryl esters. The alkyl groups may be straight chains, branched chains, and/or contain rings. Examples of esters include, but are not limited to, tetracycline esters of ethanoic acid, propanoic acid, pentanoic acid, hexanoic acid, 2-cyclopentane ethanoic acid, cyclopentanoic acid, cycloheptanoic acid, 2-methyl propanoic acid, cyclohexanoic acid, and adamantane 2-carboxylic acid. In other embodiments, R5 is hydrogen.
In an embodiment, the substituted tetracycline compounds used in the methods and compositions of the invention are substituted sancycline compounds, e.g., with substitution at the, for example, 2, 7 and/or 9 position. In substituted sancycline compounds of the invention, R2′, R3, R10, R11, and R12 are each hydrogen or a prodrug moiety; R4 is dialkylamino and R4′ is hydrogen; X is CR6R6′; and R2, R5, R6′, and R8 are each, generally, hydrogen. For 7-substituted sancycline compounds, R9 may be hydrogen. In another embodiment, R4 is hydrogen.
In one embodiment, R7 is substituted or unsubstituted aryl, e.g., heteroaryl, phenyl, etc. Examples of R7 substituents include substituents which allow the substituted tetracycline compound to perform its intended function. Examples of such substituents include, but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl. In certain embodiments, the phenyl is substituted with at least one alkyl, amino, heterocycle, alkoxy, halogen, nitro, alkoxycarbonyl, dialkylamino, or alkylamino.
In another embodiment, R7 is substituted or unsubstituted heteroaryl. Examples of heteroaromatic groups include both monocyclic and polycyclic (e.g., multicylic rings), such as, but not limited to, furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, pyridinyl, pyrazolyl, benzodioxazolyl, benzoxazolyl, benzothiazolyl, benzoimidazolyl, methylenedioxyphenyl, indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, pyrazolyl, oxazolyl, isooxazolyl, naphthridinyl, thiazolyl, isothiazolyl, and deazapurinyl. In an embodiment, R7 is benzofuranyl. Examples of substituents include all substituents which allow the tetracycline compound to perform its intended function, such as but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl. In an embodiment, R7 is thienyl. R7 may also be substituted or unsubstituted heterocyclic, e.g., morpholinyl, piperazinyl, piperidinyl, etc.
In another embodiment, R7 is substituted or unsubstituted, branched, straight chain or cyclic alkyl. Examples of substituents include substituents which allow the substituted tetracycline compound to perform its intended function, such as, but not limited to, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, trialkylsilyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl. In certain embodiments, the substituents include heterocycles, substituted and unsubstituted phenyl, a hydroxy, and combinations thereof. The substituents of the alkyl R7 may also be further substituted, if chemically possible, with the substituents for R7 groups listed above. Examples of alkyl R7 groups include C1-C15 groups, C1-C10 groups, C1-C7 groups, etc., such as, but not limited to, 2-ethyl pentyl, methyl, ethyl, propyl, pentyl, hexyl, heptyl, etc. Values and ranges included and/or intermediate within the ranges set forth herein are also intended to be within the scope of the present invention. For example, a C1-C7 group includes groups with 1, 2, 3, 4, 5, 6, and 7 carbons.
In one embodiment, R7 is substituted or unsubstituted alkenyl. Examples of substituents include substituents which allow the substituted tetracycline compound to perform its intended function. Examples of such substituents include, but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
In one embodiment, an alkenyl R7 moiety is substituted with a substituted or unsubstituted cyclic moiety. Cyclic moieties include both carbocyclic, heterocyclic, aryl, heteroaryl, cycloalkenyl, and cycloalkyl groups. Examples of cyclic moieties include, for example, cyclobutane, cylopentane, cyclohexane, phenyl, etc. The cyclic moiety can be substituted, e.g., with any substituent listed above for alkenyl R7 moieties.
R7 may also be linked to another tetracycline ring structure through a linking moiety. The linking moiety can be any length which allows the substituted tetracycline compound to perform its intended function. The linking moiety can be attached to the second tetracycline ring structure at any position that allows for such a substitution. In certain embodiments, the linker is alkyl, alkenyl, or alkynyl. The linker may be from about C1-C25, C1-C20, C1-C15, etc. In certain embodiments, the linker is alkynyl and the second tetracycline ring structure is sancyclyl. The term “tetracycline dimer” refers to compounds wherein two tetracycline ring structures are connected through chemical, e.g., covalent bonds, e.g., a linking moiety.
In another embodiment, R7 is substituted or unsubstituted alkynyl. Examples of substituents include substituents which allow the substituted tetracycline compound to perform its intended function, such as but are not limited to, for alkynyl R7 moieties include alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
The R7 alkynyl moiety may be substituted with a substituted or unsubstituted cyclic moiety. Cyclic moieties include both carbocyclic, heterocyclic, aryl, heteroaryl, cycloalkenyl, and cycloalkyl groups. Examples of cyclic moieties include, for example, cycloalkyls such as cyclobutane, cylopentane, cyclohexane, etc. The cyclic moiety can be substituted, e.g., with any substituent listed above for alkynyl R7 moieties. Examples of cyclic substituents for alkynyl R7 moieties include, but are not limited to, phenyl, cyclohexyl, p-nitro phenyl, p-methyl phenyl, cyclohexene, and 1-hydroxy cyclohexane.
Other examples of R7 groups include substituted and unsubstituted alkyl carbonyl groups. These groups can be further substituted with aryl, alkyl, arylamino, alkenyl, alkoxy, or other substituents which allow the substituted tetracycline compound to perform its intended function. Another example of an R7 moiety includes substituted and unsubstituted amino. The amino group can be dialkylamino, alkylamino, alkenylamino, arylamino, arylalkylamino, etc. or any other combination of substituents which allow it to perform its intended function, e.g., reduce the effective amount of a antifungal agent.
The invention also pertains to methods and pharmaceutical compositions comprising 7,9-disubstituted tetracycline compounds, e.g., tetracycline compounds wherein the 7 and 9 position are substituted. For example, the invention pertains to 7,9-substituted sancycline compounds, e.g., compounds wherein X is CR6R6′; and R2, R5, R6, R6′, and R8 are each hydrogen. The invention includes compounds wherein R9 is alkyl and R7 is substituted or unsubstituted aminomethyl. The invention includes compounds with any combination of substituents as described above for R7 combined with any possible other substituent at another position, e.g., R9.
In another embodiment, the invention pertains to substituted doxycycline compounds wherein R5 is hydroxy or alkylcarbonyloxy; X is CHR6; R6 is alkyl (e.g., lower alkyl, e.g., methyl); and R8 is hydrogen. R7 may be hydrogen or alkyl. R2 may be hydrogen or alkyl.
In one embodiment, R9 is substituted or unsubstituted alkenyl. Examples of substituents include substituents which allow the substituted tetracycline compound to perform its intended function. Examples of such substituents include alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
Other examples of R9 include substituted or unsubstituted alkyl (e.g., methyl, ethyl, propyl, t-butyl, n-butyl, i-butyl, pentyl, etc.), aryl, or any other substituent which allows the compound to perform its intended function.
In another embodiment, the invention pertains to methods and compositions which the substituted tetracycline compound is a substituted minocycline compound. Examples of these compounds include compounds wherein X is CR6R6′; R2, R5, R6, R6′, and R8 are each hydrogen, and R7 is dialkyl amino, e.g., dimethyl amino. In certain embodiments, the substituent may comprise one or more nitrogen atoms.
In an embodiment, R9 is substituted or unsubstituted aryl (e.g., phenyl biaryl, heteroaryl, etc.) or aralkyl. R9 may be substituted or unsubstituted heteroaryl. Examples of heteroaromatic groups include both monocyclic and polycyclic (e.g., multicyclic rings), such as, but not limited to, furanyl, imidazolyl, benzothiophenyl, benzofuranyl, quinolinyl, isoquinolinyl, pyridinyl, pyrazolyl, benzodioxazolyl, benzoxazolyl, benzothiazolyl, benzoimidazolyl, methylenedioxyphenyl, indolyl, thienyl, pyrimidyl, pyrazinyl, purinyl, pyrazolyl, oxazolyl, isooxazolyl, naphthridinyl, thiazolyl, isothiazolyl, and deazapurinyl. In an embodiment, R7 is benzofuranyl. Examples of substituents include all substituents which allow the tetracycline compound to perform its intended function, such as but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl. In an embodiment, R7 is thienyl. R7 may also be substituted or unsubstituted heterocyclic, e.g., morpholinyl, piperazinyl, piperidinyl, etc. In one embodiment, the aryl R9 moiety is substituted or unsubstituted phenyl.
Other examples of R9 moieties include substituted and unsubstituted, cyclic, branched or straight chain alkyl (e.g., C1-C15, C1-C10, e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, 2-cyclopentane ethyl, etc.). Examples of substituents include, but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl. Examples of substituents include those listed above substituents selected from the group consisting of amido, alkyl, aminoalkyl, heterocycle, carboxylic acid, formyl, chlorine, fluorine, or acetyl.
Other examples of R9 include both substituted and unsubstituted or unsubstituted alkenyl or alkynyl. Examples of substituents include, but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl. In one embodiment, the alkynyl R9 moiety is substituted with one or more substituents selected from the group consisting of substituted and unsubstituted aryl, substituted and unsubstituted alkyl, carboxylic acid, cycloalkyl, cycloalkenyl, or alkoxycarbonyl.
In another embodiment, R9 is substituted or unsubstituted alkyl or alkylamino. For example, R9 may be C1-C15 alkyl, C1-C10 alkyl, etc. In other embodiment, R9 may be substituted with groups such as aminoalkyl, hydroxy, halogens and other substituents which allow the substituted tetracycline compounds to perform their intended function. Examples of substituents include, but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
In another embodiment, R9c is hydrogen, Z is S or O, and Z′ is NH. In an embodiment, R9a comprises substituted or unsubstituted phenyl. Examples of substituents for the substituted phenyl include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
In other embodiments, R9 may be heterocyclic, e.g., morpholinyl, pyridinyl, pyrazinyl, piperidinyl, etc. These substituents may further be substituted with substituents such as, but not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl.
In a further embodiment, the substituted tetracycline compound of the invention include substituted methacycline compounds, e.g., wherein X is C═CR13Y; and R2, R5, R6, R6′, R8, and Y are each hydrogen. R7 and R9 may also be hydrogen or another moiety which allows for the substituted tetracycline compounds of the invention to perform their intended function.
In one embodiment, R13 is substituted or unsubstituted aryl, e.g., phenyl, biaryl, heteroaryl, etc. Examples of substituents include those which allow the substituted tetracycline compound to perform its intended function. Examples, include but are not limited to, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, alkyloxycarbonyl, carboxy, arylcarbonyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aminoalkyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, silyl, aminocarbonyl, alkylthiocarbonyl, phosphate, aralkyl, phosphonato, phosphinato, cyano, amino, acylamino, amido, imino, sulfhydryl, alkylthio, sulfate, arylthio, thiocarboxylate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, cyano, azido, heterocyclyl, alkylaryl, aryl and heteroaryl. In a further embodiment, the substituent is methyl or alkoxy.
In a further embodiment, the substituted tetracycline compounds of Formula (I) include compounds with large hydrophobic moieties at the 7, 9 or 13 position. The hydrophobic moieties may be partially sterically rigid (e.g., contain double or triple bonds, or contain one or more rings). For example, the compounds may comprise a substituted or unsubstituted aryl (e.g., heteroaryl, phenyl, etc. ring) group or one or more alkyl groups. In another embodiment, the compounds may comprise a group with one or more nitrogen or other heteroatoms. In a further embodiment, the compound may be a 9-substituted minocycline compound. The substituted tetracycline compounds may comprise any combination of substituents shown in Table 2.
In another embodiment, the invention also pertains to 4-dedimethylaminotetracycline compounds with the substituents described herein or shown in Table 2 (e.g., compounds with the same substituents as described herein or in Table 2, except at the R4 position where the shown dimethylamino group is a hydrogen.)
Examples of substituted tetracycline compounds which can be used in the methods of the invention are shown below and in Table 2.
##STR00003## ##STR00004## ##STR00005## ##STR00006## ##STR00007## ##STR00008## ##STR00009## ##STR00010## ##STR00011## ##STR00012## ##STR00013## ##STR00014## ##STR00015## ##STR00016## ##STR00017## ##STR00018## ##STR00019## ##STR00020## ##STR00021## ##STR00022## ##STR00023## ##STR00024## ##STR00025## ##STR00026## ##STR00027## ##STR00028##
The substituted tetracycline compounds of the invention can be synthesized using the methods described in Example 1, the following schemes, and art recognized techniques. All novel substituted tetracycline compounds described herein are included in the invention as compounds.
##STR00029##
9- and 7-substituted tetracyclines can be synthesized by the method shown in Scheme 1. As shown in Scheme 1,9- and 7-substituted tetracycline compounds can be synthesized by treating a tetracycline compound (e.g., doxycycline, 1A), with sulfuric acid and sodium nitrate. The resulting product is a mixture of the 7-nitro and 9-nitro isomers (1B and 1C, respectively). The 7-nitro (1B) and 9-nitro (1C) derivatives are treated by hydrogenation using hydrogen gas and a platinum catalyst to yield amines 1D and 1E. The isomers are separated at this time by conventional methods. To synthesize 7- or 9-substituted alkenyl derivatives, the 7- or 9-amino tetracycline compound (1E and 1F, respectively) is treated with HONO, to yield the diazonium salt (1G and 1H). The salt (1G and 1H) is treated with an appropriate halogenated reagent (e.g., R9Br, wherein R9 is an aryl, alkenyl, or alkynyl moiety) to yield the desired compound (e.g., in Scheme 1,7-cyclopent-1-enyl doxycycline (1H) and 9-cyclopent-1-enyl doxycycline (1I)).
##STR00030##
As shown in Scheme 2, tetracycline compounds of the invention wherein R7 is a carbamate or a urea derivative can be synthesized using the following protocol. Sancycline (2A) is treated with NaNO2 under acidic conditions forming 7-nitro sancycline (2B) in a mixture of positional isomers. 7-nitrosancycline (2B) is then treated with H2 gas and a platinum catalyst to form the 7-amino sancycline derivative (2C). To form the urea derivative (2E), isocyanate (2D) is reacted with the 7-amino sancycline derivative (2C). To form the carbamate (2G), the appropriate acid chloride ester (2F) is reacted with 2C.
##STR00031##
As shown in Scheme 3, tetracycline compounds of the invention, wherein R7 is a heterocyclic (i.e. thiazole) substituted amino group can be synthesized using the above protocol. 7-amino sancycline (3A) is reacted with Fmoc-isothiocyanate (3B) to produce the protected thiourea (3C). The protected thiourea (3C) is then deprotected yielding the active sancycline thiourea (3D) compound. The sancycline thiourea (3D) is reacted with an α-haloketone (3E) to produce a thiazole substituted 7-amino sancycline (3F).
##STR00032##
7-alkenyl tetracycline compounds, such as 7-alkynyl sancycline (4A) and 7-alkenyl sancycline (4B), can be hydrogenated to form alkyl 7-substituted tetracycline compounds (e.g., 7-alkyl sancycline, 4C). Scheme 4 depicts the selective hydrogenation of the 7-position double or triple bond, in saturated methanol and hydrochloric acid solution with a palladium/carbon catalyst under pressure, to yield the product.
##STR00033##
In Scheme 5, a general synthetic scheme for synthesizing 7-position aryl derivatives is shown. A Suzuki coupling of an aryl boronic acid with an iodosancycline compound is shown. An iodo sancycline compound (5B) can be synthesized from sancycline by treating sancycline (5A) with at least one equivalent N-iodosuccinimide (NIS) under acidic conditions. The reaction is quenched, and the resulting 7-iodo sancycline (5B) can then be purified using standard techniques known in the art. To form the aryl derivative, 7-iodo sancycline (5B) is treated with an aqueous base (e.g., Na2CO3) and an appropriate boronic acid (5C) and under an inert atmosphere. The reaction is catalyzed with a palladium catalyst (e.g., Pd(OAc)2). The product (5D) can be purified by methods known in the art (such as HPLC). Other 7-aryl and alkynyl tetracycline compounds can be synthesized using similar protocols. Furthermore, 7- and 9-carbonylated compounds can be synthesized using art recognized techniques.
The 7-substituted tetracycline compounds of the invention can also be synthesized using Stille cross couplings. Stille cross couplings can be performed using an appropriate tin reagent (e.g., R—SnBu3) and a halogenated tetracycline compound, (e.g., 7-iodosancycline). The tin reagent and the iodosancycline compound can be treated with a palladium catalyst (e.g., Pd(PPh3)2Cl2 or Pd(AsPh3)2Cl2) and, optionally, with an additional copper salt, e.g., CuI. The resulting compound can then be purified using techniques known in the art.
##STR00034##
The compounds of the invention can also be synthesized using Heck-type cross coupling reactions. As shown in Scheme 6, Heck-type cross-couplings can be performed by suspending a halogenated tetracycline compound (e.g., 6-iodosancycline, 6A) and an appropriate palladium or other transition metal catalyst (e.g., Pd(OAc)2 and CuI) in an appropriate solvent (e.g., degassed acetonitrile). The substrate, a reactive alkene (6B) or alkyne (6D), and triethylamine are then added and the mixture is heated for several hours, before being cooled to room temperature. The resulting 7-substituted alkenyl (6C) or 7-substituted alkynyl (6E) tetracycline compound can then be purified using techniques known in the art.
##STR00035##
To prepare 7-(2′-Chloro-alkenyl)-tetracycline compounds, the appropriate 7-(alkynyl)-sancycline (7A) is dissolved in saturated methanol and hydrochloric acid and stirred. The solvent is then removed to yield the product (7B).
##STR00036##
As depicted in Scheme 8,5-esters of 9-substituted tetracycline compounds can be formed by dissolving the 9-substituted compounds (8A) in strong acid (e.g. HF, methanesulphonic acid, and trifluoromethanesulfonic acid) and adding the appropriate carboxylic acid to yield the corresponding esters (8B).
##STR00037##
As shown in Scheme 9, methacycline (9A) can be reacted with a phenylboronic acid in the presence of a palladium catalyst such as Pd(OAc)2 to form a 13 aryl substituted methacycline compound. The resulting compound can then be purified using techniques known in the art such as preparative HPLC and characterized.
As shown in Scheme 10 below, 7 and 9 aminomethyl tetracyclines may be synthesized using reagents such as hydroxymethyl-carbamic acid benzyl ester.
##STR00038##
The term “alkenyl” includes unsaturated aliphatic groups, including straight-chain alkenyl groups, branched-chain alkenyl groups, cycloalkenyl(alicyclic) groups, alkenyl substituted cycloalkyl or cycloalkenyl groups, and cycloalkenyl substituted alkyl or alkenyl groups. The term alkenyl further includes alkenyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen, sulfur or phosphorous atoms. In preferred embodiments, a straight chain or branched chain alkenyl group has 10 or fewer carbon atoms in its backbone (e.g., C1-C10 for straight chain, C3-C10 for branched chain), and more preferably 6 or fewer. Likewise, preferred cycloalkenyl groups have from 4-7 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure, e.g., cyclopentene or cyclohexene.
The term “alkyl” includes saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl(alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen, sulfur or phosphorous atoms. In preferred embodiments, a straight chain or branched chain alkyl has 10 or fewer carbon atoms in its backbone (e.g., C1-C10 for straight chain, C3-C10 for branched chain), and more preferably 6 or fewer. Likewise, preferred cycloalkyls have from 4-7 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
Moreover, the term alkyl includes both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. Cycloalkyls can be further substituted, e.g., with the substituents described above. An “alkylaryl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl(benzyl)).
The term “aryl” includes aryl groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, benzoxazole, benzothiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Aryl groups also include polycyclic fused aromatic groups such as naphthyl, quinolyl, indolyl, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles”, “heteroaryls” or “heteroaromatics”. The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., tetralin).
The terms “alkenyl” and “alkynyl” include unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively. Examples of substituents of alkynyl groups include, for example alkyl, alkenyl (e.g., cycloalkenyl, e.g., cyclohenxenyl), and aryl groups.
Unless the number of carbons is otherwise specified, “lower alkyl” as used herein means an alkyl group, as defined above, but having from one to three carbon atoms in its backbone structure. Likewise, “lower alkenyl” and “lower alkynyl” have similar chain lengths.
The terms “alkoxyalkyl”, “polyaminoalkyl” and “thioalkoxyalkyl” include alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms.
The terms “polycyclyl” or “polycyclic radical” refer to two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety.
The term “heteroatom” includes atoms of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.
The term “alkylsulfinyl” include groups which have one or more sulfinyl (SO) linkages, typically 1 to about 5 or 6 sulfinyl linkages. Advantageous alkylsulfinyl groups include groups having 1 to about 12 carbon atoms, preferably from 1 to about 6 carbon atoms.
The term “alkylsulfonyl” includes groups which have one or more sulfonyl (SO2) linkages, typically 1 to about 5 or 6 sulfonyl linkages. Advantageous alkylsulfonyl groups include groups having 1 to about 12 carbon atoms, preferably from 1 to about 6 carbon atoms.
The term “alkanoyl” includes groups having 1 to about 4 or 5 carbonyl groups. The term “aroyl” includes aryl groups, such as phenyl and other carbocyclic aryls, which have carbonyl substituents. The term “alkaroyl” includes aryl groups with alkylcarbonyl substituents, e.g., phenylacetyl.
The structures of some of the substituted tetracycline compounds used in the methods and compositions of the invention include asymmetric carbon atoms. The isomers arising from the chiral atoms (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis.
In one embodiment, the invention pertains to methods for treating fungal associated disorder in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound in combination with an antifungal agent such that the subject is treated for the fungal associated disorder.
The language “effective amount” of a substituted tetracycline compound and/or an antifungal agent is that amount necessary or sufficient to inhibit the growth of fungus, or treat a fungus associated disorder, e.g., in a subject, e.g., prevent the various morphological and somatic symptoms of a fungal associated disorder. The effective amount can vary depending on such factors as the size and weight of the subject, the type of disorder, or the particular substituted tetracycline compound and/or antifungal agent. For example, the choice of the substituted tetracycline compound and/or antifungal agent can affect what constitutes an “effective amount”. One of ordinary skill in the art would be able to study the aforementioned factors and make the determination regarding the effective amount of the substituted tetracycline compound and/or antifungal agent without undue experimentation. An in vitro assay as described in Example 2 below or an assay similar thereto (e.g., differing in choice of fungus) also can be used to determine an “effective amount” of a substituted tetracycline compound and/or antifungal agent. The ordinarily skilled artisan would select an appropriate amount of a substituted tetracycline compound for use in the aforementioned in vitro assay.
The term “subject” any organism which may benefit from the inhibition of a fungus or which is capable of having a fungal associated disorder. Examples of subjects include not only animals, such as mammals, birds, fish, etc., but plants which may be adversely effected by the presence of a fungus.
The term “mammal” includes, but is not limited to, ruminants (e.g., cattle and goats), mice, rats, hamsters, dogs, cats, horses, pigs, sheep, lions, tigers, bears, monkeys, chimpanzees, and, in a preferred embodiment, humans. The mammal may be immunocompetent or immunocompromised, e.g., suffering from an immunodeficiency. For example, the mammal may have AIDS or may have previously or concurrently undergone chemotherapy. In another embodiment, the mammal may be elderly or young. The mammal may or may not be suffering from a fungal associated disorder. The tetracycline compounds may be administered to a mammal susceptible to a fungal associated disorder to prevent the occurrence of the disorder.
The language “fungal associated disorder” includes disorders which are related to the presence of fungus in a subject Examples of fungal associated disorders in animals include topical fungal infections caused by, e.g., Candida, and dermatophytes such as Trichophyton, Microsporum or Epidermophyton, or in mucosal infections caused by Candida albicans (e.g., oral thrush and vaginal candidiasis). The substituted tetracycline compounds of the invention are also useful for treatment of systemic fungal infections caused by, for example, Candida albicans, Cryptococcus neoformans, Aspergillus flavus, Aspergillus fumigatus, Coccidioides, Paracoccidioides, Histoplasma or Blastomyces. The substituted tetracycline compounds of the invention are particularly useful for treating fungal infections in immunocompromised patients such as patients with viral infections such as AIDS, CMV, and influenza, cancer patients receiving chemotherapy or radiotherapy, transplant patients receiving antirejection agents, and patients that have received toxic chemicals, metals and radiation exposure.
Other fungal associated disorders include aspergillosis, candidosis, chromomycosis, coccidioidiocycosis, cryptocococcosis, entomophthoromycosis, epizootic lymphangitis, geotrichosis, histoplasmosis, mucormycosis, mycetoma, north american blastomycosis, oomycosis, paecilimycosis, penicilliosis, rhinosporidiosis, and sprotrichiosis in animals. In an embodiment, the substituted tetracycline compounds of the invention can be included in feed for the livestock, such that normal consumption of said feed provides about 1 mg to about 200 mg of at least one of the substituted tetracycline compounds of the invention per kg of animal per day.
The term “in combination with” an antifungal agent is intended to include simultaneous administration of the substituted tetracycline compound and the antifungal agent, administration of the antifungal agent first, followed by the substituted tetracycline compound and administration of the substituted tetracycline compound first, followed by the antifungal agent. The antifungal agent can be administered by the same or one or more different routes than the tetracycline. The antifungal agent and the tetracycline compound may be administered at an appropriate interval (e.g., an interval selected such that the compounds of the invention are allowed to perform their intended function, e.g., the substituted tetracycline compound and the antifungal agent are allowed to interact synergistically).
The invention also pertains to a method for treating a fungal associated disorder in a mammal. The method includes administering to a mammal a synergistically effective amount of a substituted tetracycline compound in combination with an effective amount amphotericin B, such that said mammal is treated for said fungal associated disorder. In one embodiment, the tetracycline compound is a compound of formula (I). In another embodiment, the tetracycline compound is a tetracycline compound shown in Table 2.
The invention also pertains to pharmaceutical compositions comprising a synergistically effective amount of a substituted tetracycline compound, an effective amount of an antifungal agent, and, optionally, a pharmaceutically acceptable carrier.
The term “synergistically effective amount” is the amount of a substituted tetracycline compound of the invention necessary to increase the antifungal activity of the antifungal agent, such that the fungal associated disorder is treated.
The language “pharmaceutically acceptable carrier” includes substances capable of being coadministered with the substituted tetracycline compound and the antifungal agent, and which allows the antifungal agent and the substituted tetracycline compounds to perform their intended function, e.g., treat or prevent a fungal associated disorder. Examples of such carriers include solutions, solvents, dispersion media, delay agents, emulsions and the like. The use of such media for pharmaceutically active substances are well known in the art. Any other conventional carrier suitable for use with the tetracycline compounds of the present invention are included. The pharmaceutically acceptable carrier may be formulated such that it releases one or more of the active components over a desirable length of time, e.g., time release, by methods known in the art.
For example, one or more compounds of the invention may be administered alone to a subject, or more typically a compound of the invention will be administered as part of a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral or other desired administration and which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compounds.
Substituted tetracycline compounds and antifungal agents may be administered to a subject in a protonated and water-soluble form, e.g., as a pharmaceutically acceptable salt of an organic or inorganic acid, e.g., hydrochloride, sulfate, hemi-sulfate, phosphate, nitrate, acetate, oxalate, citrate, maleate, mesylate, etc. Also, where an appropriate acidic group is present on a substituted tetracycline compound or antifungal agent of the invention, a pharmaceutically acceptable salt of an organic or inorganic base can be employed such as an ammonium salt, or salt of an organic amine, or a salt of an alkali metal or alkaline earth metal such as a potassium, calcium or sodium salt.
Therapeutic compounds can be administered to a subject in accordance with the invention by any of a variety of routes. Topical (including transdermal, buccal or sublingual), oral, parenteral (including intraperitoneal, subcutaneous, intravenous, intradermal or intramuscular injection) are generally preferred.
For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
For parenteral application, particularly suitable are solutions, preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories. Therapeutic compositions will be formulated in sterile form in multiple or single dose formats such as being dispersed in a fluid carrier such as sterile physiological saline or 5% saline dextrose solutions commonly used with injectables.
For enteral application, particularly suitable are tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or the like can be used wherein a sweetened vehicle is employed. Sustained release compositions can be formulated including those wherein the active component is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc.
For topical applications, the substituted tetracycline compound and antifungal agents can be suitably admixed in a pharmacologically inert topical carrier such as a gel, an ointment, a lotion or a cream. Such topical carriers include water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils. Other possible topical carriers are liquid petrolatum, isopropylpalmitate, polyethylene glycol, ethanol 95%, polyoxyethylene monolauriate 5% in water, sodium lauryl sulfate 5% in water, and the like. In addition, materials such as anti-oxidants, humectants, viscosity stabilizers and the like also may be added if desired.
The actual preferred amounts of active compounds used in a given therapy will vary according to the specific compound being utilized, the particular compositions formulated, the mode of application, the particular site of administration, etc. Optimal administration rates for a given protocol of administration can be readily ascertained by those skilled in the art using conventional dosage determination tests conducted with regard to the foregoing guidelines.
In general, compounds of the invention for treatment can be administered to a subject in dosages used in prior tetracycline therapies. See, for example, the Physicians' Desk Reference. For example, a suitable effective dose of one or more compounds of the invention will be in the range of from 0.01 to 100 milligrams per kilogram of body weight of recipient per day, preferably in the range of from 0.1 to 50 milligrams per kilogram body weight of recipient per day, more preferably in the range of 1 to 20 milligrams per kilogram body weight of recipient per day. The desired dose is suitably administered once daily, or several sub-doses, e.g. 2 to 5 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule.
It will also be understood that normal, conventionally known precautions will be taken regarding the administration of tetracyclines and antifungal agents generally to ensure their efficacy under normal use circumstances. Especially when employed for therapeutic treatment of humans and animals in vivo, the practitioner should take all sensible precautions to avoid conventionally known contradictions and toxic effects. Thus, the conventionally recognized adverse reactions of gastrointestinal distress and inflammations, the renal toxicity, hypersensitivity reactions, changes in blood, and impairment of absorption through aluminum, calcium, and magnesium ions should be duly considered in the conventional manner.
In a still further aspect, the substituted tetracycline compounds and antifungal agents of the present invention can also be used in agricultural compositions, for example, compositions for plants and seeds to treat or prevent a variety of plant pathogenic fungi, including rusts, mildews, and molds. Generally, the compounds of the present invention are dispensed in the form of dusting powders, granules, seed dressings, aqueous solutions, dispersions or emulsions, dips, sprays, aerosols or smokes. Compositions may also be supplied in the form of dispersible powders, granules or grains, or concentrates for dilution prior to use. Such compositions may contain such conventional carriers, diluents or adjuvants as are known and acceptable in agriculture and horticulture, and they are manufactured in accordance with conventional procedures. The compositions typically contain from 0.01 to 10 wt %, preferably 0.1 to 1 wt. % of the active ingredient. The compositions may also incorporate other active ingredients, for example, compounds having herbicidal or insecticidal activity or a further fungicide. The compounds and compositions can be applied in a number of ways, for example, they can be applied directly to the plant foliage, stems, branches, seeds or roots or to the soil or other growing medium and they may be used not only to eradicate disease, but also prophylactically to protect the plants or seeds from attack. For field use, likely application rates of active ingredient are about 100 to 10,000 g/acre.
The invention also pertains to methods of killing fungus, by contacting the fungus with a synergistically effective amount of a substituted tetracycline compound and a effective amount of an antifungal agent, such that said fungus is killed.
The present invention is further illustrated by the following examples. These examples are provided to aid in the understanding of the invention and are not to be construed as limitations thereof.
The following example discusses methods of synthesizing the tetracycline compounds of the invention. Other compounds of the invention can be synthesized using techniques discussed in the application and/or by using art recognized methods.
Experimental
Melting points were taken on a MeI-Temp capillary melting point apparatus and are uncorrected. Nuclear magnetic resonance (1H NMR) spectra were recorded at 300 MHz on a Bruker Avance spectrometer. The chemical shift values are expressed in δ values (ppm) relative to tetramethylsilane or 3-(trimethylsilyl)-1-propanesulfonic acid, sodium salt, as either an internal or external standard using CDCl3, DMSO-d6, or MeOH-d4 as the solvent. Column chromatography was performed according to the method of Still using Baker “flash” grade silica gel (40 μm) that was treated with a saturated solution of Na2EDTA, washed with water, filtered and dried in an oven at 130° C. for three hours prior to use. Analytical TLC separations employed the use of 0.25 mm silica gel plates with florescence indicator obtained from J. T. Baker Chemical Co., Phillipsburg, N.J., that were pretreated by immersion into a saturated solution of Na2EDTA for five minutes and reactivated at 130° C. for three hours. Solvent systems used were as follows: 50:50:5 CHCl3/MeOH/5% Na2EDTA (lower phase) (I), 65:20:5, CHCl3/MeOH/Na2EDTA (lower phase) (II). Visualization of TLC was accomplished by 0.5% aqueous Fast Blue BB salt and heating at 130° C. for 5 minutes. Analytical HPLC was performed on a Waters Bondapak C18 reverse phase column by using two Varian SD 100 HPLC pumps at a 1.6 mL/min flow rate controlled by software. Detection was by UV absorption with Model 441 absorbance detector operating at 280 nm. Mobile phases used followed a linear gradient from 30% to 100% methanol over 30 minutes at 1.6 mL/min flow rate followed by isocratic elution with MeOH; solvent system A: 0.02 M Na2HPO4+0.001 M Na2EDTA adjusted to pH 4.5 with H3PO3; solvent system B: 100% MeOH. Semipreparative HPLC separations used a Waters semipreparative C18 reverse-phase column at a flow rate of 6.4 mL/min. Low and high resolution mass spectra were performed on a PE Mariner spectrometer (Nelson et al., J. Med. Chem. (1993) 36(3):374).
7 Iodo Sancycline
One gram of sancycline was dissolved in 25 mL of TFA (trifluoroacetic acid) that was cooled to 0 C (on ice). 1.2 equivalents of N-iodosuccinimide (NIS) was added to the reaction mixture and reacted for forty minutes. The reaction was removed from the ice bath and was allowed to react at room temperature for an additional five hours. The mixture was then analyzed by HPLC and TLC, was driven to completion by the stepwise addition of NIS. After completion of the reaction, the TFA was removed in vacuo and 3 mL of MeOH was added to dissolve the residue. The methanolic solution was the added slowly to a rapidly stirring solution of diethyl ether to form a greenish brown precipitate. The 7-iodo isomer of sancycline was purified by treating the 7-iodo product with activated charcoal, filtering through Celite, and subsequent removal of the solvent in vacuo to produce the 7-isomer compound as a pure yellow solid in 75% yield.
MS (M+H) (formic acid solvent) 541.3.
\Rt: Hypersil C18 BDS Column, 11.73
1H NMR (Methanol d4-300 MHz) δ 7.87-7.90 (d, 1H), 6.66-6.69 (d, 1H), 4.06 (s, 1H), 2.98 (s, 6H), 2.42 (m, 1H), 2.19 (m, 1H), 1.62 (m, 4H), 0.99 (m, 2H)
Methacycline (1.0 mmol), PdCl2 (0.14 mmol), and CuCl2 (0.90 mmol) were dissolved in 20 ml of MeOH and heated under nitrogen atmosphere. After 1 hour, the 4-trifluoromethylphenyl boronic acid (2.0 mmol) was added to it and the reaction mixture was heated for another 6-10 hours. The reactions was monitored by TLC, and analytical HPLC. The reaction mixture was then cooled down to the room temperature and was passed through a bed of celite. Evaporation of the solvent gave a yellow-brown solid, which was purified using preparative HPLC (CH3CN:MeOH:H2O). Evaporation of the solvent from the fractions indicated the right peak for the expected product, gave a yellow solid, which was again dissolved in MeOH and purged with HCl gas. After evaporation of MeOH, the yellow material was dried under vacuum for several hours.
7-iodosancycline (0.28 mM), Pd(OAc)2 and 1 0 mL of MeOH are added to a flask with a stir bar and the system degassed 3× using argon. Na2CO3 (0.8 mM) dissolved in water and argon degassed is added via syringe is added along with 2,5-dimethoxy phenylboronic acid (0.55 mM) in MeOH that was also degassed. The reaction was followed by HPLC for 2 hours and cooled to room temperature. The solution was filtered, and dried to produce a crude mixture. The solid was dissolved in dimethylformamide and injected onto a preparative HPLC system using C18 reverse-phase silica. The solvent was removed in vacuo to yield the product plus salts. The salts were removed by extraction into 50:25:25 water, butanol, ethyl acetate and dried in vacuo. This solid was dissolved in MeOH and the HCl salt made by bubbling in HCl gas.
To a solution of 200 mg of 7-(3-nitrophenyl) sancycline in 50 mL methanol, 10 mg of 10% palladium on charcoal catalyst was added. The reaction mixture was shaken under 40 psi hydrogen pressure for 2 hours and was then filtered followed by concentration. The residue was further purified by preparative HPLC. 35 mg was isolated as the HCl salt and the structure was proved by MNR and LC-MS to be 7-(3-aminophenyl) sancycline.
A flask was charged with 7-iodosancycline (3.0 g, 4.57 mmol), Pd(OAc)2 (0.102 g, 0.46 mmol), CuI (0.044 g, 0.23 mmol), and P(o-Tol)3 (0.278 g, 0.91 mmol) and the contents were suspended in anhydrous acetonitrile. After purging this mixture with dinitrogen at 60° C. (bath temperature), 1,7-octadiyne (0.305 mL, 2.29 mmol) was added to it, followed by the addition of triethylamine. The dark colored solution was stirred at 60° C. for 3 h, filtered through a bed of celite, dried. A methanol: DMF:TFA (90:8:2) solution of the product (9C) was purified on preparative HPLC column. Compound AN was characterized by HPLC, MS, and 1H NMR spectroscopy.
7-iodosancycline, (0.3 mM), Pd(OAc)2, and 10 mL of MeOH was added to a flask with a stir bar and the system degassed 3× using argon. Na2CO3 (1.1 mM) dissolved in water and argon degassed was added via syringe is added along with 2,4-difluoro-phenylboronic acid (0.7 mM) in MeOH that was also degassed. The reaction was followed by HPLC for 20 minutes and cooled to room temperature. The solution was filtered, and dried to produce a crude mixture. The solid was dissolved in dimethylformamide and injected onto a preparative HPLC system using C18 reverse-phase silica. The solvent was removed in vacuo to yield the product plus salts. The salts were removed by extraction into 50:25:25 water, butanol, ethyl acetate and dried in vacuo. This solid was dissolved in MeOH and the HCl salt made by bubbling in HCl gas. The solvent was removed to produce the product.
To a solution of 9-iodo-minocycline (1.13 mmol), 50 mg tetrakis-triphenylphosphino-palladate, 50 mg copper(I) iodide, 10 mg palladium acetate and 3 ml triethylamine, 0.1 ml cyclohexenyl-acetylene was added. The reaction mixture was stirred at 60° C. for one hour, filtered through a celite bed and concentrated. The dry material was dissolved in methanol and filtered. The solution was then concentrated and purified using preparative liquid chromatography. The preparative liquid chromatography used a C18 stationary phase with eluent A: 0.1% TFA in water and eluent B: 0.1% TFA in acetonitrile. The resulting compound was determined to be compound BE as determined by standard techniques.
##STR00039##
7-I-Sancycline (1 μm, 1.86 mmol), taken in 25 mL of acetonitrile was degassed and purged with nitrogen (three times). To this suspension Pd(OAc)2 (20 mg, 0.089 mmol), CuI (10 mg, 0.053 mmol), (o-tolyl)3P (56 mg, 0.183 mmol) were added and purged with nitrogen for few minutes. Propyne (3.72 mmol) and triethylamine (1 mL) were added to the suspension. It was turned into a brown solution upon addition of Et3N. The reaction mixture was then heated to 70° C. for 3 hours. Progress of the reaction was monitored by HPLC. It was then cooled down to room temperature and was filtered through celite. Evaporation of the solvent gave a brown solid, which was then purified on preparative HPLC to give a yellow solid. The structure of this compound has been characterized using 1H NMR, HPLC, and MS.
##STR00040##
7-(2-Methylphenylethynyl)-sancycline (1 mmol) was taken in saturated solution of MeOH/HCl. To this solution 10% Pd/C was added and was subjected to hydrogenation at 50 psi for 12 hrs. It was then filtered through celite. The solvent was evaporated to give a yellow powder. Finally, it was precipitated from MeOH/diethylether. The structure of this compound has been characterized using 1H NMR, HPLC, and MS.
In a clean, dry reaction vessel, was placed 9-iodominocycline (0.762 mmoles) bis HCl salt, palladium (II) acetate (0.076 mmoles) along with 10 ml of reagent grade methanol. The solution was immediately purged, with stirring, with a stream of argon gas for approximately 5 minutes. The reaction vessel was brought to reflux and to it was sequentially added via syringe 2M potassium carbonate solution, followed by a solution of p-acetylphenyl boronic acid (1.53 mmoles) in 5 ml of reagent DMF. Both of these solutions were previously degassed with argon gas for approximately 5 minutes. The reaction was heated for 45 minutes, the progress was monitored via reverse phase HPLC. The reaction was suctioned filtered through a pad of diatomaceous earth and washed the pad with DMF. The filtrates were reduced to an oil under vacuum and residue treated with t-butylmethyl ether. Crude material was purified via reverse phase HPLC on DVB utilizing a gradient of water and methanol/acetonitrile containing 1.0% trifluoroacetic acid.
7-propynyl sancycline was dissolved in a saturated methanol hydrochloric acid solvent. The mixture was placed in a hydrogenator under 50 psi hydrogen pressure. The reaction was completed in ˜8 hours. The catalyst was filtered off, and the resulting solution was concentrated. The crude product was purified by preparative liquid chromatography using a C18 stationary phase with eluent A: 0.1% TFA in water and eluent B: 0.1% TFA in acetonitrile. The combined clean fractions are concentrated and hydrochloric acid saturated isopropanol added. The pure product is precipitated by addition of diethylether and filtered off.
To a stirred solution of 9-aminominocycline (1.6 mmol) in 30 mL of acetonitrile, benzylcyanimide (6.0 mmol) was added in one portion. The reaction mixture was first heated to refluxed at 60° C. for several hours, and continued at room temperature for 4-5 days. The guanidino product was subsequently isolated, and identified using MS, NMR and HPLC.
7-para-tert-butyl phenyl sancycline (5.0 g) was dissolved in trifluoroacetic acid (300 mL). Three equivalents of HMBC was added and the reaction was stirred at room temperature. After 72 hours, HPLC indicated that the reaction was complete. The reaction mixture was filtered to give a brown liquid which was subsequently dissolved in methanol and precipitated in diethyl ether. The solid was then purified using HPLC and the product was identified using NMR and mass spectra.
7-iodo sancycline (1.3 mg) and Pd(OAc)2 were taken in 100 mL of methanol and purged with argon for five minutes at 70° C. To this solution was added a solution of sodium carbonate (44 mg) in water (previously purged with argon). A yellow precipitate was obtained and the mixture was heated for another ten minutes. 3-Furanyl boronic acid (333 mg, solution in DMF, purged with argon) was then added and the mixture was heated for another two hours at 70° C. The reaction was monitored by MPLC/MS. When the reaction was complete, the mixture was filtered through celite and the solvent was removed to give a crude material. The crude material was purified by precipitating it with ether (200 ml). The yellow precipitate was filtered and purified using preparative HPLC. The hydrochloride salt was made by dissolving the material in MeOH/HCl and evaporating to dryness. The identity of the resulting solid was confirmed using HPLC, MS, and NMR.
Under a N2 atmosphere, a stirred solution of 9-aminomethyldoxycycline dihydrochloride (1.21 g, 2.21 mmol) in DMF (10 mL) was treated with InCl3 (0.076 g, 0.34 mmol) and phenylacetaldehyde (0.511 mL, 4.4 mmol). HPLC and LC-MS monitoring of the reaction indicated the complete consumption of the starting material over the course of twelve hours; the products being both mono-(major) and bis-(minor) substituted aminomethyldoxycycline. Methanol (10 mL) was added to quench this reaction. The reaction mixture was filtered through a bed of celite. The celite bed was subsequently washed with 5 mL of methanol twice. The combined organic washes were concentrated to about 7-8 mL and diluted with ether. The resulting amorphous solid was filtered, washed with ether (6×15 mL) and dried under vacuum to afford a red powder, which was purified by preparative HPLC. The final product, Compound RR, was characterized by HPLC, MS, and 1H NMR spectroscopic methods. MS (m/z): Theor. 577.24; Found: 578.17 (M+1).
7-ethyl-9-amino sancycline (390 mg) was dissolved in 10 mL of DMF. Triethylamine (237 μL), isobutyraldehyde (77 μL), and InCl3 (19 mg) were then added and the reaction mixture was stirred for several minutes at room temperature. Then, NaBH(OAc)3 (360 mg) was added and the reaction was continued at room temperature. LC-MS showed that the reaction was completed after two hours. The reaction was quenched with methanol and dried. The resulting solid was redissolved in methanol and purified. The product was then converted to the HCl salt. The identity of the product was confirmed using NMR, HPLC, and MS.
500 milligrams of 9-NO2 sancycline was taken in 20 mL of TFA and cooled down in an ice bath. To this solution, NIS (300 mg) was added in portions and stirred at room temperature for three hours. Once the reaction was completed, 7-iodo-9-NO2 sancycline was precipitated in diethyl ether. The yellow powder was then filtered and dried in vacuo.
7-Iodo-9-nitro-sancycline (585 mg) and PD(OAc)2 (22 mg) were taken in 20 mL of methanol and purged with argon for five minutes. To this solution, Na2CO3 (420 mg, solution in 5 mL H2O, purged with argon), was added and a yellow precipitate was obtained. The solution was stirred at 55-60° C. for five minutes. To this solution, 3-furanyl boronic acid (160 mg in 5 mL of DMF, purged with argon) was added and the reaction mixture was heated at 70° C. for three hours. The reaction mixture was then passed through celite. Evaporation of the solvent gave a brown solid, which was then recrystallized using a mixture of methanol and ether to yield 7-furanyl 9-nitro sancycline.
7-Furanyl 9-nitro sancycline (500 mg) was taken in 30 ml of methanol. To this solution, PtO2 (15 mg) was added and hydrogenated at 40 psi for three hours. It was then filtered through celite. The crude material was purified using preparative HPLC to yield 7-furanyl 9-amino sancycline.
In the Parr apparatus were placed: 9-iodosancycline trifluoroacetic acid salt (0.8 g, 1.17 mmol), NaOAc (0.64 g, 4 eq.), Pd(dppf)2Cl2, and CH2Cl2 (48 mg, 5%). The apparatus was closed, purged with CO, and then filled with CO under 450 psi. The reaction mixture was stirred for four hours at 80° C. It was then acidified with TFA and concentrated in vacuo. The product was purified by HPLC. A mixture of 3:1 epimers was obtained. The yield was 188 mg of product.
7-iodo sancycline (1.3 g) was dissolved in NMP (15 mL) and CuCN (344 mg) was added. The reaction mixture was stirred at 80° C. for 15/16 hours overnight. The reaction mixture was diluted with methanol and centrifuged to yield a grey white precipitate. The reaction mixture was then passed through Celite and washed with additional methanol. The filtrate was then concentrated and precipitated with ether. The solid obtained was then purified using preparative HPLC to yield 7-cyano sancycline in a 50/50 mixture of epimers. The structure of the product was confirmed using mass spectra and NMR.
Concentrated H2SO4 (2 mL) was added slowly to a stirred solution of gluteraldehyde (1 mL). Water (0.8 g) was added and stirred at room temperature for eighteen hours and heater to 70° C. for two hours. The mixture was then cooled to room temperature. The solution was then transferred to a solution of 9-amino minocycline in DMF (5 ml) and stirred at room temperature for two days until all starting material was consumed, as indicated by HPLC. The product was isolated and purified using standard techniques. The structure of the product was confirmed by NMR and mass spec.
Na2CO3 (0.64 g) in water (5 mL) was added to a degassed solution of 9-iodo-minocycline hydrochloride (1 g) and Pd(OAc)2 (100 mg) in methanol (10 mL). The reaction was stirred for five minutes at 60° C. 2-Formyl furan-5-boronic acid (0.3 g) in methanol (10 mL) was then added, and the reaction was allowed to proceed for four hours. The mixture was then filtered and concentrated to give a brown solid (9-(2′ formyl furanyl)-minocycline).
The brown solid (9-(2′ formyl furanyl)-minocycline, 1 g) was dissolved in 20 mL of methanol and acetic acid (2 mL) and hydroxyethyl piperazine (1 mL) was added and stirred for ten minutes at room temperature. The reaction was quenched with ether (200 mL), and the organic layer was then washed and concentrated to yield a brown oil. The brown oil was the dissolved in methanol (10 mL) and water. The mixture was the chromatographed using a CH3CN gradient to yield the product, 2-[4-(9-Minocyclin-2-yl-furan-2-ylmethyl)-piperazin-1-yl]-ethanol. The product was confirmed using MS, NMR, and HPLC.
NaCNBH3 (200 mg) was added to a stirred solution of 9-amino minoccycline H2SO4 (1 g) in methanol (4.9 mL) and acetic acid 91 mL) and stirred for five minutes at room temperature. (2-Oxo-ethoxy)-acetaldehyde (10 mL) was added dropwise and stirred for fifteen minutes at room temperature. The reaction mixture was concentrated with out heat and the residue was dissolved in 20 mL of methanol and TFA (0.5 mL). The product was obtained using preparative HPLC and converted to the HCl salt. The product was confirmed using mass spectra and NMR.
Na2CO3 (0.64 g) in water (5 mL) was added to a degassed solution of 9-iodo-minocycline hydrochloride (1 g) and Pd(OAc)2 (100 mg) in methanol (10 mL). The reaction was stirred for five minutes at 60° C. 2-Formyl furan-5-boronic acid (0.3 g) in methanol (10 mL) was then added, and the reaction was allowed to proceed for four hours. The mixture was then filtered and concentrated to give a brown solid (9-(2′ formyl furanyl)-minocycline).
The brown solid (9-(2′ formyl furanyl)-minocycline, 1 g) was dissolved in 20 mL of methanol and acetic acid (2 mL) and N′-benzyl-N,N-dimethyl ethylenediamine (1 mL) was added and stirred for ten minutes at room temperature. The reaction was quenched with ether (200 mL), and the organic layer was then washed and concentrated to yield a brown oil. The brown oil was the dissolved in methanol (10 mL) and water. The mixture was the chromatographed using a CH3CN gradient to yield the product, N-Benzyl-N,N1-dimethyl-N-(5-minocyclin-9-yl-furan-2-ylmethyl)-ethane-1,2-diamine. The product was confirmed using MS, NMR, and HPLC.
Synergetic antifungal activity of the substituted tetracycline compounds was determined by a broth microdillution technique following NCCLS (1997) Standards. Assays were setup using a Tecan Genesis robotic workstation. All drugs were dissolved in DMSO and diluted appropriately. Drug concentration ranged from 0.125 to 64 μg/mL in 2 fold serial dilutions. Each tetracycline was tested at 10 concentrations ranging from 0.125 to 64 μg/mL. The compounds were tested for their antifungal activity against Candida albicans (ATCC#90028). Amphotericin B was added to all wells of the plate at a concentration of 10 fold less than the amphotericin B MIC (0.5 μg/mL).
The strains tested include those listed in Table 1.
TABLE 1
Genus
Species
ATCC/FGSC #
Aspergillus
fumigatus
ATCC 13073 (Fresenius)
Aspergillus
nidulans
FGSCA991 (wt)
Candida
albicans
ATCC 90028
Candida
albicans
PCI-1
Candida
albicans
PCI-17
Candida
albicans
ATCC 36082
Candida
glabrata
ATCC 90030
Candida
guilliermondii
ATCC 14242
Candida
krusei
ATCC 96685
Candida
krusei
ATCC 90878
Candida
lusitaniae
ATCC 24347
Candida
parapsilosis
ATCC 22109
Candida
tropicalis
ATCC 14246
Candida
tropicalis
ATCC 28707
Cryptococcus
neoformans
ATCC 90012
Cryptococcus
neoformans
ATCC 90013
Issatchenkia
orientalis
ATCC 6258
Neurospora
crassa
FGSC853
The results are shown in Table 2. For each compound, * represents good antifungal activity against the particular fungus, ** represents very good inhibition of the fungus, and *** represents excellent inhibition of a particular fungus. Each of the compounds in Table 2 exhibited synergistic behavior with amphotericin B for at least one strain of fungi.
A number of derivatives exhibited fractional inhibitory concentrations (FIC) values in the range of 0.063-0.125. The fractional inhibition values are a measure of the enhancement of the amphotericin B antifungal activity. Compounds which exhibit FIC's in the range of 0.063-0.125 allows for a 8-10 fold reduction in the effective amount of amphotericin required for antifungal activity.
TABLE 2
Asper-
Can-
Can-
Can-
Can-
Can-
Crypto-
Saccha-
In
Asper-
gillus
Asper-
dida
Can-
dida
Can-
dida
dida
dida
coccus
Issa-
romyces
Vitro
gillus
fumi-
gillus
albi-
dida
guillier-
dida
lusi-
para-
trop-
neo-
tchenkia
cere-
Cyto-
ID
STRUCTURE
flavus
gatus
terreus
cans
glabrata
mondii
krusei
taniae
psilosis
icalis
formans
orientalis
visiae
toxicity
A
##STR00041##
***
**
B
##STR00042##
***
**
C
##STR00043##
**
**
D
##STR00044##
**
**
E
##STR00045##
***
**
F
##STR00046##
***
**
G
##STR00047##
**
**
H
##STR00048##
**
**
I
##STR00049##
*
**
J
##STR00050##
***
**
K
##STR00051##
**
**
L
##STR00052##
***
**
M
##STR00053##
*
**
N
##STR00054##
**
**
O
##STR00055##
**
**
P
##STR00056##
***
**
Q
##STR00057##
***
**
R
##STR00058##
*
**
S
##STR00059##
***
**
T
##STR00060##
***
**
U
##STR00061##
**
**
V
##STR00062##
**
**
W
##STR00063##
***
**
X
##STR00064##
***
**
Y
##STR00065##
***
**
Z
##STR00066##
***
*
AA
##STR00067##
**
**
**
AB
##STR00068##
*
**
AC
##STR00069##
***
**
AD
##STR00070##
***
**
AE
##STR00071##
*
**
AF
##STR00072##
**
**
AG
##STR00073##
***
**
AH
##STR00074##
***
**
AI
##STR00075##
**
**
AJ
##STR00076##
**
**
AK
##STR00077##
***
*
AL
##STR00078##
**
**
AM
##STR00079##
**
**
AN
##STR00080##
**
**
AO
##STR00081##
***
**
AP
##STR00082##
***
**
AQ
##STR00083##
***
**
AR
##STR00084##
**
**
AS
##STR00085##
**
**
AT
##STR00086##
***
**
AU
##STR00087##
***
**
AV
##STR00088##
*
**
AW
##STR00089##
**
**
AX
##STR00090##
***
**
AY
##STR00091##
***
**
AZ
##STR00092##
***
**
BA
##STR00093##
***
**
BB
##STR00094##
***
**
BC
##STR00095##
***
**
BD
##STR00096##
***
**
BE
##STR00097##
***
**
BF
##STR00098##
**
**
BG
##STR00099##
**
**
BH
##STR00100##
**
**
BI
##STR00101##
**
**
BJ
##STR00102##
***
**
BK
##STR00103##
***
**
BL
##STR00104##
**
*
BM
##STR00105##
**
***
**
BN
##STR00106##
***
*
BO
##STR00107##
***
**
BP
##STR00108##
**
**
BQ
##STR00109##
**
**
BR
##STR00110##
***
**
BS
##STR00111##
*
**
BT
##STR00112##
**
**
BU
##STR00113##
**
**
BV
##STR00114##
**
**
BW
##STR00115##
***
**
BX
##STR00116##
***
**
BY
##STR00117##
***
**
BZ
##STR00118##
*
**
CA
##STR00119##
**
**
CB
##STR00120##
**
**
CD
##STR00121##
**
**
CE
##STR00122##
*
**
CF
##STR00123##
*
***
**
CG
##STR00124##
***
**
CH
##STR00125##
***
**
CI
##STR00126##
**
**
CJ
##STR00127##
**
**
CK
##STR00128##
**
*
CL
##STR00129##
**
**
CM
##STR00130##
***
**
CN
##STR00131##
*
*
CO
##STR00132##
**
*
CQ
##STR00133##
***
**
CR
##STR00134##
**
**
CS
##STR00135##
***
**
CT
##STR00136##
***
**
CU
##STR00137##
**
**
CV
##STR00138##
**
**
CW
##STR00139##
***
**
CX
##STR00140##
**
*
CY
##STR00141##
***
**
CZ
##STR00142##
**
**
DA
##STR00143##
***
*
DB
##STR00144##
***
**
DC
##STR00145##
**
**
DD
##STR00146##
**
**
DE
##STR00147##
**
**
DF
##STR00148##
***
***
**
DG
##STR00149##
**
**
DH
##STR00150##
***
**
DI
##STR00151##
**
**
DK
##STR00152##
***
**
DL
##STR00153##
***
**
DM
##STR00154##
*
**
DN
##STR00155##
***
**
DO
##STR00156##
***
**
DP
##STR00157##
**
**
DQ
##STR00158##
***
**
DR
##STR00159##
***
*
DS
##STR00160##
***
**
DT
##STR00161##
**
**
DU
##STR00162##
**
**
DV
##STR00163##
**
**
DW
##STR00164##
***
**
DX
##STR00165##
***
**
DY
##STR00166##
**
**
DZ
##STR00167##
***
**
EA
##STR00168##
***
**
EB
##STR00169##
**
*
EC
##STR00170##
**
**
***
***
***
**
*
ED
##STR00171##
*
**
EF
##STR00172##
***
**
EG
##STR00173##
***
**
EH
##STR00174##
***
**
EI
##STR00175##
***
*
EJ
##STR00176##
***
*
EK
##STR00177##
***
**
EL
##STR00178##
**
**
EM
##STR00179##
***
**
EN
##STR00180##
**
**
EO
##STR00181##
***
**
EP
##STR00182##
***
**
EQ
##STR00183##
***
**
ER
##STR00184##
***
**
ES
##STR00185##
***
**
ET
##STR00186##
***
**
EU
##STR00187##
***
**
EV
##STR00188##
**
**
EW
##STR00189##
**
**
EX
##STR00190##
***
**
EY
##STR00191##
***
**
EZ
##STR00192##
**
**
FA
##STR00193##
***
**
FB
##STR00194##
***
**
FC
##STR00195##
***
**
FD
##STR00196##
***
**
FE
##STR00197##
**
**
FF
##STR00198##
***
**
FG
##STR00199##
**
***
***
***
***
*
**
**
**
FH
##STR00200##
**
*
***
**
**
**
*
FI
##STR00201##
**
**
FJ
##STR00202##
***
***
**
FK
##STR00203##
**
**
FL
##STR00204##
***
**
FM
##STR00205##
**
*
FN
##STR00206##
**
***
***
***
***
**
*
FO
##STR00207##
***
**
FP
##STR00208##
*
***
*
FQ
##STR00209##
**
**
FR
##STR00210##
***
**
FS
##STR00211##
**
**
FT
##STR00212##
*
**
FU
##STR00213##
**
**
FV
##STR00214##
**
**
FW
##STR00215##
*
***
**
FX
##STR00216##
**
**
**
FY
##STR00217##
*
**
FZ
##STR00218##
*
**
GA
##STR00219##
**
**
GB
##STR00220##
***
**
GC
##STR00221##
**
***
**
GD
##STR00222##
***
**
GE
##STR00223##
**
**
GF
##STR00224##
**
**
GG
##STR00225##
**
**
GH
##STR00226##
***
**
GI
##STR00227##
***
**
GJ
##STR00228##
*
**
GK
##STR00229##
**
**
GL
##STR00230##
**
**
GM
##STR00231##
***
**
GN
##STR00232##
**
**
GO
##STR00233##
**
***
**
***
**
GP
##STR00234##
**
***
***
***
***
***
*
*
GQ
##STR00235##
**
**
*
GR
##STR00236##
**
*
GS
##STR00237##
**
**
GT
##STR00238##
**
**
***
***
**
**
*
GU
##STR00239##
*
**
GV
##STR00240##
**
*
GW
##STR00241##
***
**
GX
##STR00242##
***
**
GY
##STR00243##
***
*
GZ
##STR00244##
***
**
HA
##STR00245##
**
**
**
*
***
**
**
**
*
**
HB
##STR00246##
**
**
HC
##STR00247##
***
**
HD
##STR00248##
***
***
***
***
**
HE
##STR00249##
**
**
HF
##STR00250##
***
***
***
***
**
HG
##STR00251##
**
**
HH
##STR00252##
**
*
HI
##STR00253##
*
*
HJ
##STR00254##
**
**
HK
##STR00255##
*
***
**
HL
##STR00256##
*
*
HM
##STR00257##
*
*
HN
##STR00258##
*
**
HO
##STR00259##
***
**
HP
##STR00260##
***
***
***
***
***
**
**
HQ
##STR00261##
**
*
HR
##STR00262##
**
*
HS
##STR00263##
**
***
***
***
***
**
**
*
HT
##STR00264##
***
***
***
***
***
**
**
*
HU
##STR00265##
**
**
***
***
***
**
*
HV
##STR00266##
***
**
HW
##STR00267##
***
**
HX
##STR00268##
***
**
HY
##STR00269##
**
*
HZ
##STR00270##
**
**
**
*
*
IA
##STR00271##
***
***
*
IB
##STR00272##
**
***
**
**
*
IC
##STR00273##
**
**
***
***
***
**
*
ID
##STR00274##
*
***
***
***
***
*
IE
##STR00275##
**
***
***
***
***
***
*
*
IF
##STR00276##
***
***
***
***
***
**
***
*
**
IG
##STR00277##
***
**
IH
##STR00278##
***
**
IJ
##STR00279##
**
*
IK
##STR00280##
***
***
***
***
***
*
*
IL
##STR00281##
***
***
**
IM
##STR00282##
*
*
IN
##STR00283##
***
**
IO
##STR00284##
**
**
IP
##STR00285##
**
*
IQ
##STR00286##
*
*
IR
##STR00287##
***
**
IS
##STR00288##
**
*
IT
##STR00289##
**
**
***
***
***
**
*
IU
##STR00290##
***
*
IV
##STR00291##
**
*
IW
##STR00292##
***
*
IX
##STR00293##
***
**
IY
##STR00294##
**
**
***
***
**
**
*
IZ
##STR00295##
*
*
JA
##STR00296##
**
*
***
***
**
**
*
JB
##STR00297##
***
**
JC
##STR00298##
***
**
JD
##STR00299##
***
*
JE
##STR00300##
***
***
**
JF
##STR00301##
***
**
JG
##STR00302##
**
***
***
**
*
JH
##STR00303##
***
**
JI
##STR00304##
***
*
JJ
##STR00305##
*
***
***
***
***
***
**
***
*
JK
##STR00306##
***
*
JL
##STR00307##
***
*
JM
##STR00308##
***
*
JN
##STR00309##
***
**
JO
##STR00310##
*
**
*
JP
##STR00311##
*
*
JQ
##STR00312##
**
**
JR
##STR00313##
**
*
JS
##STR00314##
*
*
JT
##STR00315##
**
**
*
JU
##STR00316##
**
***
**
JV
##STR00317##
***
**
JW
##STR00318##
***
**
JX
##STR00319##
**
*
JY
##STR00320##
**
**
*
JZ
##STR00321##
**
**
KA
##STR00322##
***
**
KB
##STR00323##
***
**
KC
##STR00324##
**
**
KD
##STR00325##
***
**
KE
##STR00326##
**
**
KF
##STR00327##
**
**
KG
##STR00328##
**
**
KH
##STR00329##
**
**
**
KI
##STR00330##
***
**
KJ
##STR00331##
**
**
KK
##STR00332##
***
**
KL
##STR00333##
***
**
KM
##STR00334##
**
**
KN
##STR00335##
***
**
KO
##STR00336##
***
*
KP
##STR00337##
***
*
KQ
##STR00338##
***
**
KR
##STR00339##
*
*
KS
##STR00340##
**
**
KT
##STR00341##
*
**
KU
##STR00342##
*
*
KV
##STR00343##
**
*
KW
##STR00344##
**
**
KX
##STR00345##
**
**
KY
##STR00346##
**
**
KZ
##STR00347##
**
*
LA
##STR00348##
**
**
LB
##STR00349##
**
**
LC
##STR00350##
*
*
*
LD
##STR00351##
*
*
*
LE
##STR00352##
**
**
LF
##STR00353##
**
**
LG
##STR00354##
**
**
LH
##STR00355##
**
**
LI
##STR00356##
**
**
LJ
##STR00357##
**
*
LK
##STR00358##
**
**
LL
##STR00359##
**
*
LM
##STR00360##
**
***
**
LN
##STR00361##
**
**
LO
##STR00362##
**
**
LP
##STR00363##
**
**
LQ
##STR00364##
**
**
*
LR
##STR00365##
**
*
LS
##STR00366##
**
*
LT
##STR00367##
*
*
LU
##STR00368##
**
*
LV
##STR00369##
*
*
LW
##STR00370##
**
*
LX
##STR00371##
**
*
LY
##STR00372##
**
**
LZ
##STR00373##
**
**
MA
##STR00374##
**
**
MB
##STR00375##
**
*
MC
##STR00376##
***
***
*
MD
##STR00377##
**
***
*
ME
##STR00378##
**
***
*
MF
##STR00379##
**
***
*
MG
##STR00380##
**
***
*
MH
##STR00381##
**
*
MI
##STR00382##
*
*
MJ
##STR00383##
**
*
MK
##STR00384##
*
**
***
***
*
*
*
**
**
ML
##STR00385##
*
*
MM
##STR00386##
*
*
MN
##STR00387##
***
***
***
***
**
***
**
MO
##STR00388##
***
**
MP
##STR00389##
**
***
***
*
**
MQ
##STR00390##
***
**
MR
##STR00391##
**
**
MS
##STR00392##
***
**
MT
##STR00393##
**
*
MU
##STR00394##
***
**
MV
##STR00395##
***
**
MW
##STR00396##
***
**
MX
##STR00397##
***
**
MY
##STR00398##
***
***
**
MZ
##STR00399##
*
***
***
***
*
NA
##STR00400##
*
***
***
***
*
NB
##STR00401##
**
***
***
*
NC
##STR00402##
***
*
ND
##STR00403##
*
***
***
***
*
NE
##STR00404##
*
***
***
***
**
*
NF
##STR00405##
***
**
NG
##STR00406##
***
**
NH
##STR00407##
**
**
**
NI
##STR00408##
**
**
NJ
##STR00409##
***
**
NK
##STR00410##
*
**
***
***
*
NL
##STR00411##
*
***
***
***
*
NM
##STR00412##
***
**
NN
##STR00413##
**
*
NO
##STR00414##
**
**
NP
##STR00415##
***
***
**
NQ
##STR00416##
**
**
NR
##STR00417##
**
**
NS
##STR00418##
***
**
NT
##STR00419##
***
**
NU
##STR00420##
***
**
NV
##STR00421##
***
**
NW
##STR00422##
***
**
NX
##STR00423##
***
**
NY
##STR00424##
*
**
NZ
##STR00425##
**
**
OA
##STR00426##
***
**
OB
##STR00427##
***
***
**
OC
##STR00428##
**
**
OD
##STR00429##
***
**
OE
##STR00430##
**
**
OF
##STR00431##
***
**
OG
##STR00432##
***
**
OH
##STR00433##
**
**
OI
##STR00434##
**
**
OJ
##STR00435##
***
**
OK
##STR00436##
***
**
OL
##STR00437##
**
**
OM
##STR00438##
**
**
ON
##STR00439##
**
**
OO
##STR00440##
***
**
OP
##STR00441##
***
**
OQ
##STR00442##
***
**
OR
##STR00443##
***
*
OS
##STR00444##
**
**
OT
##STR00445##
**
*
OU
##STR00446##
**
*
OV
##STR00447##
***
*
OW
##STR00448##
***
*
OX
##STR00449##
***
**
OY
##STR00450##
*
**
OZ
##STR00451##
**
**
PA
##STR00452##
*
*
PB
##STR00453##
***
*
PC
##STR00454##
**
*
PD
##STR00455##
***
*
PE
##STR00456##
**
**
PF
##STR00457##
***
**
PG
##STR00458##
***
*
PH
##STR00459##
**
*
PI
##STR00460##
**
**
PJ
##STR00461##
**
*
PK
##STR00462##
***
**
PL
##STR00463##
***
**
PM
##STR00464##
**
**
PN
##STR00465##
***
**
PO
##STR00466##
***
**
PP
##STR00467##
***
**
PQ
##STR00468##
*
*
PR
##STR00469##
*
*
PS
##STR00470##
**
*
PT
##STR00471##
***
*
PU
##STR00472##
***
**
PV
##STR00473##
**
**
PW
##STR00474##
***
**
PX
##STR00475##
***
**
PY
##STR00476##
***
*
PZ
##STR00477##
***
**
QA
##STR00478##
***
**
QB
##STR00479##
***
**
QC
##STR00480##
**
**
QD
##STR00481##
**
**
*
QE
##STR00482##
***
***
**
QF
##STR00483##
***
**
QG
##STR00484##
***
***
*
QH
##STR00485##
***
**
QI
##STR00486##
**
**
QJ
##STR00487##
*
**
**
QK
##STR00488##
***
*
QL
##STR00489##
***
***
*
QM
##STR00490##
**
**
*
QN
##STR00491##
***
*
QO
##STR00492##
**
**
QP
##STR00493##
***
**
QQ
##STR00494##
***
***
*
QR
##STR00495##
***
**
QS
##STR00496##
**
**
*
QT
##STR00497##
***
**
QU
##STR00498##
***
**
QV
##STR00499##
***
**
QW
##STR00500##
**
**
**
QX
##STR00501##
**
**
**
QY
##STR00502##
**
**
*
QZ
##STR00503##
***
***
*
RA
##STR00504##
***
***
**
RB
##STR00505##
**
**
*
RC
##STR00506##
**
**
*
RD
##STR00507##
**
**
*
RE
##STR00508##
***
***
**
RF
##STR00509##
**
*
RG
##STR00510##
***
***
*
RH
##STR00511##
**
*
RI
##STR00512##
**
**
RJ
##STR00513##
**
***
**
***
**
RK
##STR00514##
**
*
RL
##STR00515##
*
***
**
*
RM
##STR00516##
***
**
RN
##STR00517##
*
**
RO
##STR00518##
**
*
RP
##STR00519##
*
*
RQ
##STR00520##
*
*
RR
##STR00521##
**
*
RS
##STR00522##
**
*
***
*
**
**
RT
##STR00523##
***
**
RU
##STR00524##
*
*
RV
##STR00525##
*
**
RW
##STR00526##
**
*
RX
##STR00527##
*
*
RY
##STR00528##
*
***
***
*
RZ
##STR00529##
*
*
SA
##STR00530##
*
**
*
*
SB
##STR00531##
**
*
SC
##STR00532##
*
*
SD
##STR00533##
**
*
SE
##STR00534##
*
***
***
**
*
SF
##STR00535##
***
**
SG
##STR00536##
*
*
SH
##STR00537##
*
*
SI
##STR00538##
*
*
SJ
##STR00539##
**
**
**
*
SK
##STR00540##
*
*
SL
##STR00541##
**
**
SM
##STR00542##
**
*
SN
##STR00543##
***
**
SO
##STR00544##
**
**
*
**
SP
##STR00545##
**
*
SQ
##STR00546##
**
*
SR
##STR00547##
***
**
SS
##STR00548##
***
**
ST
##STR00549##
**
***
**
*
SU
##STR00550##
*
**
SV
##STR00551##
*
*
SW
##STR00552##
*
**
**
**
*
SX
##STR00553##
**
**
**
**
**
SY
##STR00554##
*
**
*
**
*
SZ
##STR00555##
**
*
**
*
TA
##STR00556##
**
*
**
*
TB
##STR00557##
**
**
**
*
TC
##STR00558##
*
*
*
TD
##STR00559##
*
*
*
TE
##STR00560##
**
**
**
**
*
TF
##STR00561##
**
***
**
***
*
TG
##STR00562##
*
*
*
*
TH
##STR00563##
**
**
**
**
*
TI
##STR00564##
*
*
*
*
TJ
##STR00565##
**
**
**
*
TK
##STR00566##
*
*
*
TL
##STR00567##
***
***
**
***
**
TM
##STR00568##
***
***
**
***
**
TN
##STR00569##
**
**
*
**
**
TO
##STR00570##
**
**
**
*
TP
##STR00571##
**
**
*
**
*
TQ
##STR00572##
*
*
TS
##STR00573##
**
**
**
**
**
TT
##STR00574##
**
***
**
***
**
TU
##STR00575##
**
**
*
TV
##STR00576##
**
**
**
***
**
TW
##STR00577##
**
**
*
TX
##STR00578##
***
***
*
**
**
TY
##STR00579##
*
*
*
TZ
##STR00580##
***
***
***
**
UC
##STR00581##
**
**
*
UD
##STR00582##
**
*
*
UE
##STR00583##
***
***
**
***
**
UF
##STR00584##
***
***
***
***
**
UH
##STR00585##
*
**
***
*
**
UI
##STR00586##
***
***
***
**
**
UJ
##STR00587##
**
**
**
*
UK
##STR00588##
***
**
***
**
**
UL
##STR00589##
**
**
**
**
UM
##STR00590##
***
**
**
***
**
UN
##STR00591##
**
**
**
**
UO
##STR00592##
***
***
**
***
**
UQ
##STR00593##
***
***
***
**
UR
##STR00594##
***
**
**
US
##STR00595##
***
**
**
UT
##STR00596##
**
**
**
UV
##STR00597##
***
***
***
**
UW
##STR00598##
**
**
**
*
UX
##STR00599##
*
*
UY
##STR00600##
**
**
***
**
UZ
##STR00601##
*
**
**
***
**
VA
##STR00602##
**
**
**
**
VB
##STR00603##
**
**
*
**
**
VC
##STR00604##
**
**
**
**
VD
##STR00605##
**
**
**
**
VE
##STR00606##
**
**
**
**
**
VF
##STR00607##
**
**
**
**
**
VG
##STR00608##
*
**
VH
##STR00609##
**
**
*
**
**
VJ
##STR00610##
**
**
**
**
VK
##STR00611##
***
***
**
***
**
COS-1 and CHO Cell suspensions were prepared, seeded into 96-well tissue culture treated black-walled microtiter plates (density determined by cell line), and incubated overnight at 37° C., in 5% CO2 and approximately 95% humidity. The following day serial dilutions of drug were prepared under sterile conditions and transferred to cell plates. Cell/Drug plates were incubated under the above conditions for 24 hours. Following the incubation period, media/drug was aspirated and 50 ml of Resazurin was added. Plates were then incubated under the above conditions for 2 hours and then in the dark at room temperature for an additional 30 minutes. Fluorescence measurements were taken (excitation 535 nm, emission 590 nm). The IC50 (concentration of drug causing 50% growth inhibition) was then calculated for each compound.
In Table 2, toxicities greater than >25 μg/ml are represented by * and toxicities less than 25 μg/mL are represented by **.
The following assay is used to determine the efficacy of the tetracycline compounds against common bacteria. 2 mg of each compound is dissolved in 100 μl of DMSO. The solution is then added to cation-adjusted Mueller Hinton broth (CAMHB), which results in a final compound concentration of 200 μg per ml. The tetracycline compound solutions are diluted to 504 volumes, with a test compound concentration of 0.098 μg/ml. Optical density (OD) determinations are made from fresh log-phase broth cultures of the test strains. Dilutions are made to achieve a final cell density of 1×106 CFU/ml. At OD=1, cell densities for different genera should be approximately:
E. coli 1×109 CFU/ml
S. aureus 5×108 CFU/ml
Enterococcus sp. 2.5×109 CFU/ml
50 μl of the cell suspensions are added to each well of microtiter plates. The final cell density should be approximately 5×105 CFU/ml. These plates are incubated at 35° C. in an ambient air incubator for approximately 18 hr. The plates are read with a microplate reader and are visually inspected when necessary. The MIC is defined as the lowest concentration of the tetracycline compound that inhibits growth.
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of the present invention and are covered by the following claims. The contents of all references, patents, and patent applications cited throughout this application are hereby incorporated by reference. The appropriate components, processes, and methods of those patents, applications and other documents may be selected for the present invention and embodiments thereof.
Draper, Michael, Nelson, Mark L.
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 2980584, | |||
| 2990331, | |||
| 3062717, | |||
| 3165531, | |||
| 3454697, | |||
| 3557280, | |||
| 3674859, | |||
| 3957980, | Oct 26 1972 | Pfizer Inc. | Doxycycline parenteral compositions |
| 4018889, | Jan 02 1976 | Pfizer Inc. | Oxytetracycline compositions |
| 4024272, | Sep 06 1974 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Tetracyclic compounds |
| 4126680, | Apr 27 1977 | Pfizer Inc. | Tetracycline antibiotic compositions |
| 4168206, | May 02 1977 | Philadelphia College of Osteopathic Medicine | Impregnated disk method for testing antifungal susceptibility |
| 5362754, | Nov 12 1992 | Board of Regents, The University of Texas System | M-EDTA pharmaceutical preparations and uses thereof |
| 5532227, | Nov 17 1992 | Research Foundation of State University of New York, The | Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes |
| 5639742, | Apr 02 1993 | 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | |
| 5688516, | Nov 12 1992 | Board of Regents, The University of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
| 5789395, | Aug 30 1996 | New York University | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
| 5834450, | Jan 12 1995 | Pfizer Inc. | 9- (substituted amino) -alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics |
| 5989522, | Jan 31 1989 | Yissum Research & Development Company of the Hebrew University of | Oral antifungal preventative, and method of use |
| 6500812, | Jul 07 2000 | PARATEK PHARMACEUTICALS, INC | 13-substituted methacycline compounds |
| 6509319, | Aug 26 1997 | Board of Regents, The University of Texas System | EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections |
| 6617318, | Sep 14 1999 | Trustees of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| 6624168, | Jul 07 2000 | Trustees of Tufts College | 7,8 and 9-substituted tetracycline compounds |
| 6642270, | May 15 2000 | PARATEK PHARMACEUTICALS, INC | 7-substituted fused ring tetracycline compounds |
| 6683068, | Mar 13 2001 | PARATEK PHARMACEUTICALS, INC | 7, 9-substituted tetracycline compounds |
| 6818634, | Mar 31 2000 | Trustees of Tufts College | 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds |
| 6818635, | Jul 07 2000 | PARATEK PHARMACEUTICALS, INC | 7-substituted tetracycline compounds |
| 6833365, | Jan 24 2000 | Trustees of the Tufts College | Tetracycline compounds for treatment of Cryptosporidium parvum related disorders |
| 6841546, | Mar 14 2001 | PARATEK PHARMACEUTICALS, INC | Substituted tetracycline compounds as antifungal agents |
| 6846939, | Jul 07 2000 | PARATEK PHARMACEUTICALS, INC | 9-substituted minocycline compounds |
| 6849615, | Sep 14 1999 | Paratek Pharmaceuticals, Inc.; Trustees of Tufts College | 13-substituted methacycline compounds |
| 7001918, | Mar 13 2001 | Paratek Pharmaceuticals, Inc. | 7-pyrrolyl tetracycline compounds and methods of use thereof |
| 7045507, | Mar 14 2001 | PARATEK PHARMACEUTICALS, INC | Substituted tetracycline compounds as synergistic antifungal agents |
| 7056902, | Jan 08 2002 | PARATEK PHARMACEUTICALS, INC | 4-dedimethylamino tetracycline compounds |
| 7067681, | Sep 14 1999 | Trustees of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| 7094806, | Jul 07 2000 | TUFTS COLLEGE, TRUSTEES OF | 7, 8 and 9-substituted tetracycline compounds |
| 20020031601, | |||
| 20020123637, | |||
| 20020128237, | |||
| 20020128238, | |||
| 20020132798, | |||
| 20020147182, | |||
| 20040048835, | |||
| 20040063674, | |||
| 20040092490, | |||
| 20040138183, | |||
| 20040152674, | |||
| 20040176334, | |||
| 20040214800, | |||
| 20040214801, | |||
| 20040242548, | |||
| 20040266740, | |||
| 20050020545, | |||
| 20050026875, | |||
| 20050026876, | |||
| 20050038002, | |||
| 20050070510, | |||
| 20050119235, | |||
| 20050137174, | |||
| 20050143352, | |||
| 20050143353, | |||
| 20050187198, | |||
| 20050215532, | |||
| 20050250744, | |||
| 20050282787, | |||
| 20050288262, | |||
| 20060003971, | |||
| DE2814974, | |||
| DE2820983, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jun 14 2002 | DRAPER, MICHAEL | PARATEK PHARMACEUTICALS, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 026229 | /0596 | |
| Jun 14 2002 | NELSON, MARK L | PARATEK PHARMACEUTICALS, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 026229 | /0596 | |
| Sep 16 2004 | Paratek Pharmaceuticals, Inc. | (assignment on the face of the patent) | / | |||
| Jul 06 2009 | PARATEK PHARMACEUTICALS, INC | MIDCAP FINANCIAL, LLC | SECURITY AGREEMENT | 022917 | /0112 | |
| Oct 09 2009 | MIDCAP FINANCIAL, LLC | PARATEK PHARMACEUTICALS, INC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 023348 | /0621 | |
| Mar 08 2013 | PARATEK PHARMACEUTICALS, INC | MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC | NOTICE | 029940 | /0106 | |
| Mar 07 2014 | PARATEK PHARMACEUTICALS, INC | HBM HEALTHCARE INVESTMENTS CAYMAN LTD , AS COLLATERAL AGENT | SECURITY INTEREST SEE DOCUMENT FOR DETAILS | 032448 | /0001 | |
| Oct 31 2014 | HBM HEALTHCARE INVESTMENTS CAYMAN LTD , AS COLLATERAL AGENT | PARATEK PHARMACEUTICALS, INC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 034113 | /0910 | |
| Dec 22 2014 | MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO PC | PARATEK PHARMACEUTICALS, INC | TERMINATION OF LIEN ON PATENTS | 034700 | /0377 |
| Date | Maintenance Fee Events |
| Dec 15 2014 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Dec 14 2018 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Jan 30 2023 | REM: Maintenance Fee Reminder Mailed. |
| Jul 17 2023 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Jun 14 2014 | 4 years fee payment window open |
| Dec 14 2014 | 6 months grace period start (w surcharge) |
| Jun 14 2015 | patent expiry (for year 4) |
| Jun 14 2017 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jun 14 2018 | 8 years fee payment window open |
| Dec 14 2018 | 6 months grace period start (w surcharge) |
| Jun 14 2019 | patent expiry (for year 8) |
| Jun 14 2021 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jun 14 2022 | 12 years fee payment window open |
| Dec 14 2022 | 6 months grace period start (w surcharge) |
| Jun 14 2023 | patent expiry (for year 12) |
| Jun 14 2025 | 2 years to revive unintentionally abandoned end. (for year 12) |